Galapagos NV Phase 3 study with filgotinib initiated in Crohn's disease

First patient dosed triggers $50 million milestone payment Mechelen Belgium; 22 November 2016 Galapagos NV Euronext & NASDAQ GLPG reports the first dosing of a patient in the DIVERSITY Phase...